Edition:
India

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

14.86USD
22 Jun 2018
Change (% chg)

$0.23 (+1.57%)
Prev Close
$14.63
Open
$14.57
Day's High
$14.86
Day's Low
$13.98
Volume
8,693
Avg. Vol
8,444
52-wk High
$51.90
52-wk Low
$13.98

Latest Key Developments (Source: Significant Developments)

Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE.OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​.OPIANT PHARMACEUTICALS - ROYALTY & MILESTONE PAYMENTS DUE TO SWK HOLDINGS WILL NOW BE REDUCED TO 10%.  Full Article

Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.OPIANT PHARMACEUTICALS INC - QTRLY ‍NET LOSS PER COMMON SHARE $2.77​.  Full Article

Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​.  Full Article

Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​.  Full Article

Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update.Q4 revenue $3.75 million versus $300,000.‍Opiant Pharmaceuticals Inc - appointed David O'Toole as chief financial officer​.Opiant Pharmaceuticals Inc - qtrly loss per share $0.17‍​.  Full Article

BRIEF-Opiant Pharma Reports Financial Results

* OPIANT PHARMACEUTICALS, INC. REPORTS FINANCIAL RESULTS FOR AUGUST 1, 2017, THROUGH DECEMBER 31, 2017, AND PROVIDES CORPORATE UPDATE Source text for Eikon: Further company coverage: